Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
Boye KS, Sapin H, García-Pérez LE, Rosilio M, Orsini Federici M, Heitmann E, Jung H, Aigner U, Guerci B, Giorgino F, Norrbacka K. Boye KS, et al. Among authors: sapin h. Diabetes Ther. 2020 Oct;11(10):2383-2399. doi: 10.1007/s13300-020-00908-9. Epub 2020 Sep 3. Diabetes Ther. 2020. PMID: 32880876 Free PMC article.
Genotypes and phenotypes of children with SHOX deficiency in France.
Rosilio M, Huber-Lequesne C, Sapin H, Carel JC, Blum WF, Cormier-Daire V. Rosilio M, et al. Among authors: sapin h. J Clin Endocrinol Metab. 2012 Jul;97(7):E1257-65. doi: 10.1210/jc.2011-3460. Epub 2012 Apr 19. J Clin Endocrinol Metab. 2012. PMID: 22518848
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.
Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M. Ostenson CG, et al. Among authors: sapin h. Diabetes Metab Syndr Obes. 2013 Apr 26;6:171-85. doi: 10.2147/DMSO.S41827. Print 2013. Diabetes Metab Syndr Obes. 2013. PMID: 23667315 Free PMC article.
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M. Mathieu C, et al. Among authors: sapin h. Diabetes Ther. 2013 Dec;4(2):285-308. doi: 10.1007/s13300-013-0037-8. Epub 2013 Sep 10. Diabetes Ther. 2013. PMID: 24018835 Free PMC article.
Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.
Reaney M, Mathieu C, Ostenson CG, Matthaei S, Krarup T, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M, Guerci B. Reaney M, et al. Among authors: sapin h. Health Qual Life Outcomes. 2013 Dec 26;11:217. doi: 10.1186/1477-7525-11-217. Health Qual Life Outcomes. 2013. PMID: 24369764 Free PMC article.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE, Boye KS, Rosilio M, Jung H, Heitmann E, Norrbacka K, Federici MO, Gentilella R, Guerci B, Giorgino F, Aigner U, Sapin H. García-Pérez LE, et al. Among authors: sapin h. Diabetes Ther. 2021 Jul;12(7):1929-1946. doi: 10.1007/s13300-021-01076-0. Epub 2021 Jun 7. Diabetes Ther. 2021. PMID: 34097244 Free PMC article.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Guerci B, Giorgino F, Sapin H, Boye K, Lebrec J, Federici MO, Heitmann E, Dib A, Füchtenbusch M, García-Pérez LE. Guerci B, et al. Among authors: sapin h. Diabetes Obes Metab. 2022 Dec;24(12):2373-2382. doi: 10.1111/dom.14823. Epub 2022 Aug 31. Diabetes Obes Metab. 2022. PMID: 35876235 Free PMC article.
24 results